treatment

Probiotics for SIBO – Do they Help or Harm?

bloating, dysbiosis, gut microbiome, gut support, IBS, inflammation, microbiome, probiotic sibo healing, probiotics, SIBO, supplements, treatment

If you've been struggling with SIBO (Small Intestinal Bacterial Overgrowth), you may be familiar with the uncomfortable symptoms, such as bloating, gas, pain, and unpredictable bowel movements, which can make everyday life a challenge.

Naturally, you want relief. But when it comes to probiotics for SIBO, the advice is all over the place. Some people swear by them, while others warn that probiotics could worsen symptoms by feeding the overgrowth.

So, what's the real answer? Can probiotics help with SIBO, or should you avoid them completely?

What is SIBO, and how does it feel?

SIBO happens when bacteria that should stay in the large intestine start growing in the small intestine. Since the small intestine is designed for nutrient absorption—not fermentation—this overgrowth can cause major digestive issues. (1)

Common SIBO symptoms:

Bloating (especially after eating)
Gas and distension
Diarrhea, constipation, or both
Nutrient deficiencies (B12, iron, fat-soluble vitamins)
Abdominal pain and discomfort
Brain fog and fatigue
Muscle and joint pain
Skin issues (eczema, rosacea, acne)

SIBO is often misdiagnosed as IBS because the symptoms overlap. However, IBS treatments don't always work for SIBO because they don't address bacterial overgrowth.

The underlying reasons for SIBO can also be many things, from impaired gut motility, insufficient digestive juice production, infections, and structural problems.

What are probiotics?

Probiotics are live microorganisms—mainly beneficial bacteria and yeasts—that support gut health when consumed in the right amounts. The word "probiotic" comes from the Greek "pro bios," meaning "for life."

Unlike harmful bacteria that cause infections, probiotics help balance your gut microbiome and promote better digestion, immunity, and overall health.

Probiotics benefit the gut by:

Crowding out harmful bacteria – By competing for space and nutrients, probiotics can prevent the overgrowth of pathogenic bacteria.
Enhancing digestion – Certain strains help break down food, absorb nutrients, and even produce vitamins like B12 and K2.
Supporting gut barrier function – They strengthen the gut lining, reducing leaky gut and inflammation.
Producing beneficial compounds – Many probiotics create short-chain fatty acids (SCFAs) and antimicrobial substances that support gut health.
Regulating the immune system – A balanced microbiome prevents excessive immune reactions, helping conditions like IBS, allergies, and autoimmune disorders.
and many more benefits (2) (3) (4) (5)

Types of probiotics

Probiotics come in various strains, each with different benefits.

The most common types include:

Lactobacillus & Bifidobacterium – Found in yogurt, kefir, and supplements. They aid digestion and boost immunity.
Saccharomyces boulardii – A probiotic yeast that fights harmful bacteria and supports gut healing.
Soil-based probiotics (Bacillus species) – Hardy strains that survive stomach acid and support microbiome balance. (6)

Probiotics for SIBO – is it a yes or a no?

The biggest concern with probiotics and SIBO is that you're adding more bacteria to an overgrowth situation. Wouldn't that make things worse?

Why some experts say to avoid probiotics for SIBO:

Many probiotics contain Lactobacillus and Bifidobacterium, which may colonize the small intestine and worsen bloating.
Some strains (e.g., Lactobacillus bulgaricus, L. casei, Streptococcus thermophilus, etc.) increase histamine, triggering inflammation. (7)
Multi-strain probiotics might exacerbate symptoms instead of helping.
Certain ingredients in these products may worsen symptoms, such as prebiotics, starches, lactose, maltodextrin, etc.

Why some experts recommend probiotics for SIBO:

Certain probiotic strains produce antimicrobial compounds that fight bad bacteria. (8)
Some probiotics help improve gut motility, preventing bacterial stagnation. (9)
Probiotics may reduce inflammation, enhance gut barrier function, supporting gut healing. (10)

The best probiotic strains for SIBO

The key to using probiotics for SIBO is choosing the right strains. Research suggests that certain probiotics can reduce symptoms and even help prevent SIBO relapse.

Are there promising results that probiotics for SIBO are effective?

A pilot study compared the effectiveness of metronidazole (Flagyl) (a common antibiotic used in methanogen overgrowth) vs. a probiotic blend in 50 patients with SIBO and chronic abdominal distension.

They found that

82% of patients taking the probiotic reported symptom improvement, compared to 52% in the antibiotic group—a statistically significant difference (P = 0.036).
The probiotic contained Lactobacillus casei, Lactobacillus plantarum, Streptococcus faecalis, and Bifidobacterium brevis (Bioflora).
No major side effects were reported in either group.

This study suggests that probiotics may be more effective than metronidazole for improving SIBO-related bloating and abdominal distension in the short term. While more research is needed, probiotics could be a promising alternative or complementary approach to antibiotics in SIBO treatment. (11)

Another study investigated the effects of Bacillus clausii in patients with SIBO diagnosed via hydrogen breath test (HBT). In this study, patients were given Bacillus clausii (a spore-forming probiotic) for treatment. Results showed that Bacillus clausii normalized hydrogen breath tests at rates comparable to antibiotics. Patients also experienced symptomatic relief, particularly in bloating and gas production. (12)

Let's look at the various strains that show promising results

Lactobacillus reuteri DSM 17938

This probiotic strain has been found to have a beneficial effect on chronic constipation by massively decreasing methane production and improving gut motility. (13)
It was found to reduce abdominal pain in children. (14)
It has also been shown to prevent SIBO occurrence in patients taking proton pump inhibitors (PPIs) (a medication used to reduce stomach acid production). (15)
reuteri also has antimicrobial (produce Reuterin and other substances) properties and is effective against Helicobacter pylori, E. Coli, Clostridium difficile, and Salmonella infection. It has been suggested that L. reuteri has antiviral components and antifungal properties against Candida species and can reduce inflammation. (16)
It can produce vitamin B12 (cobalamin) and B9 (folate), which are often low in patients with SIBO. (16)

Most studies use 1 × 10⁸ to 2 × 10⁸ CFU (colony-forming units) per day. This is typically delivered in one or two doses daily.

Research suggests that taking Lactobacillus reuteri DSM 17938 for 4–8 weeks may provide benefits, especially for reducing methane production and improving gut motility in SIBO patients. (17)

An example product is BioGaia Protectis Drops (5 drops per day, which provides 1 × 10⁸ CFU of Lactobacillus reuteri DSM 17938).

Or BioGaia Gastrus that contains 200 million CFU (2 × 10⁸ CFU) per tablet of L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475. Typically used for gut motility, methane overgrowth, and H. pylori support. (for more clinical studies, check out this guide created by >>Biogaia<<

Bifidobacterium lactis HN019

This strain has been found to improve gut motility and bowel movement frequency in cases of functional constipation (18)
It reduces bloating and gas by rebalancing gut bacteria (19)
It has been reported to reduce the frequency of functional gastrointestinal symptoms in adults, including abdominal pain, nausea, constipation, diarrhea, and flatulence (17)

Clinical studies have used 1 × 10⁹ to 1 × 10¹⁰ CFU (1–10 billion CFU) per day for gut motility and digestive benefits. Some studies have used up to 17.2 billion CFU per day for improving gut transit time (19)

4–8 weeks is the typical study duration for improving constipation and bloating. Some trials suggest effects may be seen as early as 14 days, but the best results occur after a month or more.

An example of products could be Life Extension, Florassist® Probiotic, Daily Bowel Regularity.

Lactobacillus plantarum 299v

Lactobacillus plantarum 299v (LP299V) is a well-researched probiotic strain, particularly for gut health, IBS, and inflammatory conditions.

Potential benefits for SIBO & gut health:

Reduces bloating and abdominal pain in IBS patients - A randomized controlled trial found that LP299V significantly reduced bloating and pain in IBS patients (20)
Strengthens gut barrier function (reduces leaky gut) - LP299V has been shown to improve intestinal permeability, helping strengthen the gut barrier in stressed individuals (21). Many SIBO patients have leaky gut, which can worsen inflammation and food intolerances.
Reduces inflammation and modulates immune response - LP299V has been shown to lower inflammatory markers like TNF-α and IL-6 in patients with IBS (22). Chronic inflammation is common in SIBO due to bacterial toxins; LP299V may help reduce this.

Most clinical studies use 5 × 10^9 to 1 × 10^10 CFU per day (up to 100 billion CFU) per day.

Research suggests taking LP299V for 4–12 weeks provides the most benefits for gut motility, inflammation, and bloating relief. (23),(24)

An example product is Jarrow Formulas, Vegan Ideal Bowel Support, 10 Billion CFU.

Saccharomyces boulardii

Saccharomyces boulardii (S. boulardii) is a unique probiotic yeast that has been widely studied for gut health, diarrhea, and microbiome restoration. Unlike bacterial probiotics (like Lactobacillus and Bifidobacterium), S. boulardii is a non-colonizing yeast, meaning it doesn't stay in the gut long-term—it works while you take it and is eliminated within a few days after stopping supplementation.

This makes S. boulardii particularly useful in SIBO treatment, as it does not contribute to bacterial overgrowth but still provides key gut-supportive benefits. (25)

Supports SIBO antibiotic therapy without being destroyed - unlike bacterial probiotics, boulardii is not affected by antibiotics, making it an excellent choice during or after SIBO antibiotic treatment. A clinical trial showed that adding S. boulardii to antibiotic treatment like metronidazole improved SIBO eradication rates compared to antibiotics alone. (26)
In another study, in patients with decompensated cirrhosis, a 3-month course of S. boulardii eliminated SIBO in 80% of cases, compared to 23.1% in a placebo group. (27)
Reduces digestive symptoms - S. boulardii has been shown to reduce diarrhea and antibiotic-associated diarrhea significantly. (28) Hydrogen-dominant SIBO is often associated with chronic diarrhea, and S. boulardii can help regulate stool consistency.
Clinical trials show that adding S. boulardii to antibiotic therapy can improve SIBO-related diarrhea and abdominal pain faster than antibiotics alone (29).
A meta-analysis found another type of yeast, Saccharomyces cerevisiae (S. Cerevisiae CNCM I-3856), to significantly improve abdominal pain and discomfort, bloating, as well as stool consistency in IBS patients. (30)
Modulates the immune system & reduces gut inflammation – S. boulardii was shown to reduce pro-inflammatory cytokines (IL-6, TNF-α) and improve gut immune function. (31) Why does this matter for SIBO? Because SIBO triggers gut inflammation, leading to bloating, food sensitivities, and leaky gut. S. boulardii helps calm the immune response and protect the gut lining.
Supports gut microbiome balance - One of the biggest challenges in SIBO treatment is that antibiotics can kill both harmful and beneficial bacteria, leading to gut dysbiosis and a higher risk of relapse. Since S. boulardii is a yeast and not a bacterium, it is resistant to antibiotics and can help restore gut balance during and after antibiotic treatment. A randomized trial found that boulardii protected the gut microbiome from antibiotic-induced dysbiosis in healthy volunteers (32). A clinical study on patients with SIBO and IBS-D found that S. boulardii supplementation reduced harmful bacteria (Proteobacteria) and increased beneficial anti-inflammatory microbes (F. prausnitzii) (29)

How Saccharomyces boulardii is different from bacterial probiotics

Saccharomyces boulardii vs bacterial probiotics

Key takeaway: S. boulardii is ideal for SIBO patients undergoing antibiotic treatment or those who want symptom relief without increasing bacterial overgrowth.

The general recommended dosage:

Standard dose: 250–500 mg per day (equivalent to 5–10 billion CFU per day).
Higher doses (up to 1,000 mg per day) have been used in some studies for diarrhea and gut inflammation.

Duration:

During antibiotic therapy: Take S. boulardii alongside antibiotics to prevent dysbiosis and increase the rate of eradication of SIBO.
Post-SIBO treatment: Continue for 4–8 weeks to support microbiome recovery.
For chronic SIBO symptoms: May be taken long-term as needed.

An example product containing Saccharomyces boulardii is Florastor (by Biocodex), which is one of the most well-studied S. boulardii brands.

Soil-based probiotics (Bacillus strains)

Soil-based probiotics (SBOs) are spore-forming bacteria that naturally exist in the environment. Unlike traditional Lactobacillus and Bifidobacterium probiotics, SBOs are highly resilient, surviving stomach acid, antibiotics, and harsh gut conditions.

This makes SBOs particularly useful for SIBO, as they:

Do not contribute to bacterial overgrowth in the small intestine.
Resist destruction by antibiotics, so they can be used during and after SIBO treatment.
Produce antimicrobial compounds, which may help control SIBO-related bacteria.

There are a lot of types of soil-based bacteria, but the most common species are:

Bacillus Clausii
Bacillus Coagulans
Bacillus Subtilis
Bacillus indicus
Bacillus licheniformis

I want to clarify the benefits of using some of the safest and most effective species for gut health based on research, including Bacillus Clausii, Bacillus Coagulans, and Bacillus Subtilis.

Benefits of Soil-based probiotics for gut health

Bacillus clausii

Bacillus clausii is a spore-forming bacterium that is heat and shelf-stable.

Here are some of its benefits for gut health:

Helps reduce diarrhea - Evidence from clinical studies suggests that B. clausii shows effectiveness in preventing and treating diarrhea in adults and children, including diarrhea resulting from antibiotic treatment. (33)
Survives antibiotics & prevents dysbiosis (gut imbalance)- A clinical trial found that Bacillus clausii restored microbiome balance in patients taking antibiotics (34). Why it matters? Since SIBO is often treated with antibiotics, taking B. clausii during and after treatment may reduce side effects and prevent relapse.
Reduces IBS symptoms, boosts the immune system & reduces inflammation - B. clausii was shown to modulate the immune response and reduce gut inflammation in patients with IBS. They significantly reduced abdominal pain in children with IBS. (35) Many SIBO patients suffer from gut inflammation and immune dysfunction, making B. clausii a valuable strain for gut healing.
Helpful in SIBO eradication – a study involving 40 patients diagnosed with SIBO found that after taking Enterogermina for one month, 47% of participants showed a normalized glucose breath test result. (36)

General dosage & duration:

5–10 billion CFU per day
Duration: 4–8 weeks, especially during & after antibiotic therapy

Example Product: Enterogermina (Sanofi) – One of the most well-studied B. clausii probiotics, commonly used with antibiotics.

Bacillus coagulans

It is the most studied soil-based probiotic. There have been quite a few studies on its effectiveness for IBS.

Key benefits for gut health:

Reduces digestive symptoms:
- B. coagulans (MTCC 5856) was shown to have a positive effect on diarrhea in IBS patients. (37)
- B. coagulans (GBI-30, 6086) was shown to relieve abdominal pain and bloating (38).
- A clinical trial showed that Bacillus coagulans (SNZ 1969) increased gut motility and reduced constipation. (39)
A study suggests that GanedenBC30 (Bacillus coagulans) may aid in the digestion of lactose, fructose, and milk protein, potentially reducing intestinal symptoms in individuals sensitive to these carbohydrates. However, its effectiveness could be greater if more spores germinated. (40)
Effective for SIBO:
- In a clinical trial involving 30 individuals with chronic abdominal pain or diarrhea and a positive hydrogen breath test (HBT) for SIBO, B. coagulans Unique IS-2 was found to be effective. After three weeks of antibiotic therapy, participants were given either B. coagulans Unique IS-2 or a placebo for 15 days alongside maintenance antibiotics. After six months, the probiotic group showed significant improvements:
  - Gastrointestinal symptoms like belching, flatulence, and diarrhea significantly improved.
  - Abdominal pain disappeared completely.
  - 93% of individuals in the probiotic group had negative hydrogen breath tests, compared to 67% in the placebo group. (41)

General dosage & duration:

2–10 billion CFU per day
Duration: 6–8 weeks for symptom relief, but can be used long-term for gut support.

Example product: LactoSpore® (B. coagulans MTCC 5856)

Bacillus subtilis

Key benefits for gut health:

Improves gut motility – a study showed that B. Subtilis (DE111) improves occasional constipation and/or diarrhea in healthy individuals. (42)
Reduces gut symptoms – In another study, Bacillus subtilis MB40 (MB40) was shown to reduce bloating intensity, abdominal discomfort, and gas in healthy participants. (43)
Reduces abdominal pain – a study found that Medilac DS (Bacillus subtilis with Streptococcus faecium) is a safe and useful probiotic agent for the treatment of abdominal pain in patients with IBS. (44)
Helps in H. Pylori eradication - Supplementation with probiotic strains, composed of Bacillus subtilis and Streptococcus faecium, were shown to improve drug compliance, reduce side effects, and enhance the intention-to-treat eradication rate of Helicobacter pylori. (45)

General dosage & duration:

1–4 billion CFU per day
Duration: 8–12 weeks for biofilm disruption

Example product: CoreBiotic (Researched Nutritionals) – Contains Bacillus subtilis along with other SBOs.

Are soil-based probiotics safe for SIBO?

There is some concern that certain soil-based probiotics (SBOs) may persist too long in the gut or pose risks for immunocompromised individuals.

However, well-researched strains like Bacillus clausii, Bacillus coagulans, and Bacillus subtilis have shown strong safety profiles and gut health benefits, particularly for reducing inflammation, supporting digestion, and balancing the gut microbiome.

While most studies focus on IBS rather than SIBO, the overlapping symptoms (bloating, diarrhea, constipation, abdominal pain) suggest that SBOs could offer similar benefits, particularly for bloating, motility issues, and microbiome repair after antibiotic therapy. Choosing clinically studied strains and monitoring tolerance is key to safely incorporating SBOs into a SIBO recovery plan.

If you don't want to experiment with soil-based probiotic supplements, you can expose yourself to them in a natural way through gardening, touching dirt, growing organic vegetables, and spending time outdoors.

How to take probiotics for SIBO without making symptoms worse

While probiotics can be incredibly beneficial for gut healing and microbiome balance, choosing the wrong product (especially multi-strain products) or introducing it too quickly may worsen bloating, gas, or discomfort. Plus, you may need to be extra careful if you suffer from histamine issues or have other immune system-related health challenges.

Here's how to safely incorporate probiotics into your SIBO treatment plan:

Start slow and low – Introduce one strain at a time and monitor symptoms. Gradually increase over 1–2 weeks, based on tolerance.
Choose products that clearly list the strains. - Each strain should be identified on the label. For example, not just Bacillus coagulans, but Bacillus coagulans MTCC 5856.
CFU count should be visible on the label – The label should specify billions of CFUs per dose.
Includes an expiration or manufacturing date – This ensures the bacteria remain viable.
Check the ingredient list – The product should be free from common allergens like gluten and dairy, and ideally, you want to have a product without added prebiotics (like inulin) if you have SIBO.
Manufactured under Good Manufacturing Practices (GMP) – This ensures safety and quality control.
Third-party tested – Independent lab verification confirms strain accuracy and potency.
Pair with other SIBO treatments – Probiotics alone won't cure SIBO. Use them alongside dietary and lifestyle changes, treatment, addressing the root causes, and prokinetics. It should be part of a holistic approach to SIBO.

Conclusion: should you use probiotics for SIBO?

The debate over probiotics for SIBO stems from concerns that adding more microbes to an already imbalanced small intestine could worsen symptoms. However, the research suggests otherwise—when the right probiotic strains are chosen, they can enhance treatment success, support microbiome recovery, and reduce relapse risk.

Certain probiotics, such as Saccharomyces boulardii and Bacillus clausii, are safe to use during antibiotic or herbal treatments, helping to prevent gut dysbiosis.

After treatment, soil-based probiotics (SBOs) like Bacillus coagulans and Bacillus subtilis can help restore microbial balance, improve motility, and strengthen the gut lining, reducing the likelihood of SIBO returning.

While most studies have focused on IBS rather than SIBO specifically, the overlap in symptoms suggests that probiotics can offer similar benefits in regulating bloating, stool consistency, and gut function. The key is to use well-researched strains, introduce them gradually, and listen to your body's response.

Verdict: Yes, probiotics can be a valuable tool for SIBO treatment and recovery—but only when carefully selected and strategically used.

This post is only for informational purposes and is not meant to diagnose, treat, or cure any disease. I recommend always consulting your healthcare practitioner before trying any treatment or dietary changes

References

References:

Achufusi, T. G. O., Sharma, A., Zamora, E. A., & Manocha, D. (2020). Small Intestinal Bacterial Overgrowth: Comprehensive Review of Diagnosis, Prevention, and Treatment Methods. Cureus, 12(6), e8860. https://doi.org/10.7759/cureus.8860
Hill, C., Guarner, F., Reid, G. et al.The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 11, 506–514 (2014). https://doi.org/10.1038/nrgastro.2014.66
Bodke, H., & Jogdand, S. (2022). Role of Probiotics in Human Health. Cureus, 14(11), e31313. https://doi.org/10.7759/cureus.31313
Kechagia, M., Basoulis, D., Konstantopoulou, S., Dimitriadi, D., Gyftopoulou, K., Skarmoutsou, N., & Fakiri, E. M. (2013). Health benefits of probiotics: a review. ISRN nutrition, 2013, 481651. https://doi.org/10.5402/2013/481651
Gul, S., & Durante-Mangoni, E. (2024). Unraveling the Puzzle: Health Benefits of Probiotics—A Comprehensive Review. Journal of Clinical Medicine, 13(5), 1436. https://doi.org/10.3390/jcm13051436
Pandey, K. R., Naik, S. R., & Vakil, B. V. (2015). Probiotics, prebiotics and synbiotics- a review. Journal of food science and technology, 52(12), 7577–7587. https://doi.org/10.1007/s13197-015-1921-1
https://activatedprobiotics.com.au/wp-content/uploads/2024/06/AP_Histamine-Gene-Table_A4_DX.pdf
Fijan S. (2023). Probiotics and Their Antimicrobial Effect. Microorganisms, 11(2), 528. https://doi.org/10.3390/microorganisms11020528
Dimidi E, Christodoulides S, Scott SM, Whelan K. Mechanisms of Action of Probiotics and the Gastrointestinal Microbiota on Gut Motility and Constipation. Adv Nutr. 2017 May 15;8(3):484-494. doi: 10.3945/an.116.014407. PMID: 28507013; PMCID: PMC5421123.
Chen, W. C., & Quigley, E. M. (2014). Probiotics, prebiotics & synbiotics in small intestinal bacterial overgrowth: opening up a new therapeutic horizon!. The Indian journal of medical research, 140(5), 582–584.I https://pmc.ncbi.nlm.nih.gov/articles/PMC4311309/
Soifer, L. O., Peralta, D., Dima, G., & Besasso, H. (2010). Eficacia comparativa de un probiótico vs un antibiótico en la respuesta clínica de pacientes con sobrecrecimiento bacteriano del intestino y distensión abdominal crónica funcional: un estudio piloto [Comparative clinical efficacy of a probiotic vs. an antibiotic in the treatment of patients with intestinal bacterial overgrowth and chronic abdominal functional distension: a pilot study]. Acta gastroenterologica Latinoamericana, 40(4), 323–327. I https://pubmed.ncbi.nlm.nih.gov/21381407/
Gabrielli, M., Lauritano, E. C., Scarpellini, E., Lupascu, A., Ojetti, V., Gasbarrini, G., Silveri, N. G., & Gasbarrini, A. (2009). Bacillus clausii as a treatment of small intestinal bacterial overgrowth. The American journal of gastroenterology, 104(5), 1327–1328. https://doi.org/10.1038/ajg.2009.91
Ojetti, V., Petruzziello, C., Migneco, A., Gnarra, M., Gasbarrini, A., & Franceschi, F. (2017). Effect of Lactobacillus reuteri (DSM 17938) on methane production in patients affected by functional constipation: a retrospective study. European review for medical and pharmacological sciences, 21(7), 1702–1708.
Weizman, Z., Abu-Abed, J., & Binsztok, M. (2016). Lactobacillus reuteri DSM 17938 for the Management of Functional Abdominal Pain in Childhood: A Randomized, Double-Blind, Placebo-Controlled Trial. The Journal of pediatrics, 174, 160–164.e1. https://doi.org/10.1016/j.jpeds.2016.04.003
Belei, O., Olariu, L., Dobrescu, A., Marcovici, T., & Marginean, O. (2018). Is It Useful to Administer Probiotics Together With Proton Pump Inhibitors in Children With Gastroesophageal Reflux?. Journal of neurogastroenterology and motility, 24(1), 51–57. https://doi.org/10.5056/jnm17059
Mu, Q., Tavella, V. J., & Luo, X. M. (2018). Role of Lactobacillus reuteriin Human Health and Diseases. Frontiers in microbiology, 9, 757. https://doi.org/10.3389/fmicb.2018.00757
Ojetti, V., Petruzziello, C., Migneco, A., Gnarra, M., Gasbarrini, A., & Franceschi, F. (2017). Effect of Lactobacillus reuteri (DSM 17938) on methane production in patients affected by functional constipation: a retrospective study. European review for medical and pharmacological sciences, 21(7), 1702–1708.
Cheng, J., Laitila, A., & Ouwehand, A. C. (2021). Bifidobacterium animalislactis HN019 Effects on Gut Health: A Review. Frontiers in nutrition, 8, 790561. https://doi.org/10.3389/fnut.2021.790561
Waller, P. A., Gopal, P. K., Leyer, G. J., Ouwehand, A. C., Reifer, C., Stewart, M. E., & Miller, L. E. (2011). Dose-response effect of Bifidobacterium lactis HN019 on whole gut transit time and functional gastrointestinal symptoms in adults. Scandinavian journal of gastroenterology, 46(9), 1057–1064. https://doi.org/10.3109/00365521.2011.584895
Ducrotté, P., Sawant, P., & Jayanthi, V. (2012). Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World journal of gastroenterology, 18(30), 4012–4018. https://doi.org/10.3748/wjg.v18.i30.4012
Kaźmierczak-Siedlecka, K., Daca, A., Folwarski, M., Witkowski, J. M., Bryl, E., & Makarewicz, W. (2020). The role of Lactobacillus plantarum299v in supporting treatment of selected diseases. Central-European journal of immunology, 45(4), 488–493. https://doi.org/10.5114/ceji.2020.101515
Malik, M., Suboc, T. M., Tyagi, S., Salzman, N., Wang, J., Ying, R., Tanner, M. J., Kakarla, M., Baker, J. E., & Widlansky, M. E. (2018). Lactobacillus plantarum 299v Supplementation Improves Vascular Endothelial Function and Reduces Inflammatory Biomarkers in Men With Stable Coronary Artery Disease. Circulation research, 123(9), 1091–1102. https://doi.org/10.1161/CIRCRESAHA.118.313565
Stevenson, C., Blaauw, R., Fredericks, E., Visser, J., & Roux, S. (2014). Randomized clinical trial: effect of Lactobacillus plantarum 299 v on symptoms of irritable bowel syndrome. Nutrition (Burbank, Los Angeles County, Calif.), 30(10), 1151–1157. https://doi.org/10.1016/j.nut.2014.02.010
Krammer, H., Storr, M., Madisch, A., & Riffel, J. (2021). Reizdarmbehandlung mit Lactobacillus plantarum 299v: Längere Einnahme verstärkt Behandlungserfolg – Ergebnisse einer nichtinterventionellen Studie [Treatment of IBS with Lactobacillus plantarum 299v: Therapeutic success increases with length of treatment - real-life data of a non-interventional study in Germany]. Zeitschrift fur Gastroenterologie, 59(2), 125–134. https://doi.org/10.1055/a-1340-0204
Pais, P., Almeida, V., Yılmaz, M., & Teixeira, M. C. (2020). Saccharomyces boulardii: What Makes It Tick as Successful Probiotic?. Journal of fungi (Basel, Switzerland), 6(2), 78. https://doi.org/10.3390/jof6020078
García-Collinot, G., Madrigal-Santillán, E. O., Martínez-Bencomo, M. A., Carranza-Muleiro, R. A., Jara, L. J., Vera-Lastra, O., Montes-Cortes, D. H., Medina, G., & Cruz-Domínguez, M. P. (2020). Effectiveness of Saccharomyces boulardii and Metronidazole for Small Intestinal Bacterial Overgrowth in Systemic Sclerosis. Digestive diseases and sciences, 65(4), 1134–1143. https://doi.org/10.1007/s10620-019-05830-0
Efremova, I., Maslennikov, R., Zharkova, M., Poluektova, E., Benuni, N., Kotusov, A., Demina, T., Ivleva, A., Adzhieva, F., Krylova, T., & Ivashkin, V. (2024). Efficacy and Safety of a Probiotic Containing Saccharomyces boulardiiCNCM I-745 in the Treatment of Small Intestinal Bacterial Overgrowth in Decompensated Cirrhosis: Randomized, Placebo-Controlled Study. Journal of clinical medicine, 13(3), 919. https://doi.org/10.3390/jcm13030919
Billoo, A. G., Memon, M. A., Khaskheli, S. A., Murtaza, G., Iqbal, K., Saeed Shekhani, M., & Siddiqi, A. Q. (2006). Role of a probiotic (Saccharomyces boulardii) in management and prevention of diarrhoea. World journal of gastroenterology, 12(28), 4557–4560. https://doi.org/10.3748/wjg.v12.i28.4557
Bustos Fernández, L. M., Man, F., & Lasa, J. S. (2023). Impact of Saccharomyces boulardii CNCM I-745 on Bacterial Overgrowth and Composition of Intestinal Microbiota in Diarrhea-Predominant Irritable Bowel Syndrome Patients: Results of a Randomized Pilot Study. Digestive diseases (Basel, Switzerland), 41(5), 798–809. https://doi.org/10.1159/000528954
Cayzeele-Decherf, A., Pélerin, F., Leuillet, S., Douillard, B., Housez, B., Cazaubiel, M., Jacobson, G. K., Jüsten, P., & Desreumaux, P. (2017). Saccharomyces cerevisiaeCNCM I-3856 in irritable bowel syndrome: An individual subject meta-analysis. World journal of gastroenterology, 23(2), 336–344. https://doi.org/10.3748/wjg.v23.i2.336
Stier, H., & Bischoff, S. C. (2016). Influence of Saccharomyces boulardii CNCM I-745on the gut-associated immune system. Clinical and experimental gastroenterology, 9, 269–279. https://doi.org/10.2147/CEG.S111003
Kabbani, T. A., Pallav, K., Dowd, S. E., Villafuerte-Galvez, J., Vanga, R. R., Castillo, N. E., Hansen, J., Dennis, M., Leffler, D. A., & Kelly, C. P. (2017). Prospective randomized controlled study on the effects of Saccharomyces boulardii CNCM I-745 and amoxicillin-clavulanate or the combination on the gut microbiota of healthy volunteers. Gut microbes, 8(1), 17–32. https://doi.org/10.1080/19490976.2016.1267890
Acosta-Rodríguez-Bueno, C. P., Abreu Y Abreu, A. T., Guarner, F., Guno, M. J. V., Pehlivanoğlu, E., & Perez, M., 3rd (2022). Bacillus clausii for Gastrointestinal Disorders: A Narrative Literature Review. Advances in therapy, 39(11), 4854–4874. https://doi.org/10.1007/s12325-022-02285-0
Maity, C., & Gupta, A. K. (2021). Therapeutic efficacy of probiotic Alkalihalobacillus clausii088AE in antibiotic-associated diarrhea: A randomized controlled trial. Heliyon, 7(9), e07993. https://doi.org/10.1016/j.heliyon.2021.e07993
Vázquez-Frias, R., Consuelo-Sánchez, A., Acosta-Rodríguez-Bueno, C. P., Blanco-Montero, A., Robles, D. C., Cohen, V., Márquez, D., & Perez, M., 3rd (2023). Efficacy and Safety of the Adjuvant Use of Probiotic Bacillus clausii Strains in Pediatric Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Study. Paediatric drugs, 25(1), 115–126. https://doi.org/10.1007/s40272-022-00536-9
Gabrielli, M., Lauritano, E. C., Scarpellini, E., Lupascu, A., Ojetti, V., Gasbarrini, G., Silveri, N. G., & Gasbarrini, A. (2009). Bacillus clausii as a treatment of small intestinal bacterial overgrowth. The American journal of gastroenterology, 104(5), 1327–1328. https://doi.org/10.1038/ajg.2009.91
Majeed, M., Nagabhushanam, K., Natarajan, S., Sivakumar, A., Ali, F., Pande, A., Majeed, S., & Karri, S. K. (2016). Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: a double blind randomized placebo controlled pilot clinical study. Nutrition journal, 15, 21. https://doi.org/10.1186/s12937-016-0140-6
Hun L. (2009). Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS. Postgraduate medicine, 121(2), 119–124. https://doi.org/10.3810/pgm.2009.03.1984
Kang, S., Park, M. Y., Brooks, I., Lee, J., Kim, S. H., Kim, J. Y., Oh, B., Kim, J. W., & Kwon, O. (2021). Spore-forming Bacillus coagulans SNZ 1969 improved intestinal motility and constipation perception mediated by microbial alterations in healthy adults with mild intermittent constipation: A randomized controlled trial. Food research international (Ottawa, Ont.), 146, 110428. https://doi.org/10.1016/j.foodres.2021.110428
Maathuis, A. J., Keller, D., & Farmer, S. (2010). Survival and metabolic activity of the GanedenBC30 strain of Bacillus coagulans in a dynamic in vitro model of the stomach and small intestine. Beneficial microbes, 1(1), 31–36. https://doi.org/10.3920/BM2009.0009
Gabrielli, M., Lauritano, E. C., Scarpellini, E., Lupascu, A., Ojetti, V., Gasbarrini, G., Silveri, N. G., & Gasbarrini, A. (2009). Bacillus clausii as a treatment of small intestinal bacterial overgrowth. The American journal of gastroenterology, 104(5), 1327–1328. https://doi.org/10.1038/ajg.2009.91
Cuentas, A. M., Deaton, J., Davidson, J., Ardita, C. & Khan, S. The Effect of Bacillus subtilis DE111 on the Daily Bowel Movement Profile for People with Occasional Gastrointestinal Irregularity. Journal of Probiotics & Health 5, 1–4 (2017).
Penet, C., Kramer, R., Little, R., Spears, J. L., Parker, J., Iyer, J. K., Guthrie, N., & Evans, M. (2021). A Randomized, Double-blind, Placebo-controlled, Parallel Study Evaluating the Efficacy of Bacillus subtilis MB40 to Reduce Abdominal Discomfort, Gas, and Bloating. Alternative therapies in health and medicine, 27(S1), 146–157.
Kim, Y. G., Moon, J. T., Lee, K. M., Chon, N. R., & Park, H. (2006). The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 47(6), 413–419.
Park, S. K., Park, D. I., Choi, J. S., Kang, M. S., Park, J. H., Kim, H. J., Cho, Y. K., Sohn, C. I., Jeon, W. K., & Kim, B. I. (2007). The effect of probiotics on Helicobacter pylori eradication. Hepato-gastroenterology, 54(79), 2032–2036.

Probiotics for SIBO – Do they Help or Harm? Read More »

SIBO vs Celiac Disease: symptoms, diagnosis, and the critical connection you need to know

autoimmunity, bloating, celiac disease, constipation, diagnosis, diarrhea, gluten, immune system, inflammation, SIBO, small intestine, treatment

If you've ever struggled with chronic gut issues like bloating, gassiness, diarrhea, or fatigue, you know how life-altering they can be. The daily discomfort, restrictive diets, and constant anxiety about flare-ups can take a toll on both your physical and emotional well-being.

Among the myriad of gut health conditions, SIBO (Small Intestinal Bacterial Overgrowth) and celiac disease often cause confusion due to their overlapping symptoms.

Despite their similarities, these conditions have very different causes, diagnostic criteria, and treatments.

In this blog, I'll break down what SIBO vs Celiac disease is, how to tell them apart, and explore their surprising connection. Plus, I'll share the inspiring story of a client who found answers and relief after years of struggle.

SIBO vs Celiac disease main differences and similarities

What is SIBO?

Let's start with the basics. Small Intestinal Bacterial Overgrowth (SIBO) occurs when bacteria that normally live in other parts of the digestive tract—like the colon—start to overpopulate the small intestine. This imbalance can wreak havoc on your digestive system and lead to a range of debilitating symptoms, including:

Persistent bloating and gas
Abdominal pain or discomfort
Diarrhea, constipation, or alternating between the two
Fatigue and brain fog, often caused by nutrient malabsorption
Food intolerances, particularly to fermentable carbohydrates (like those found in FODMAP foods)

Living with SIBO can feel like being in an endless cycle of discomfort. You might wake up feeling "off," brace yourself for every meal, and wonder why seemingly healthy foods like cauliflower or garlic leave you doubled over with pain. For many, the restrictive diets they turn to for symptom relief can feel isolating and unsustainable.

But why does SIBO happen in the first place? Causes vary but often include:

Impaired gut motility (sometimes due to post-infectious IBS or conditions like diabetes)
Structural abnormalities (like adhesions or scar tissue from surgeries or existing conditions like Endometriosis)
Usage of certain medications, such as proton pump inhibitors (PPIs), which reduce stomach acid and can disrupt gut bacteria
Lack of defense mechanisms in the body to prevent overgrowth (low stomach acid, poor bile flow, immune dysregulation, etc.)

If left untreated, SIBO can lead to long-term nutrient deficiencies, particularly in B12, iron, and fat-soluble vitamins. Thus, early diagnosis and treatment are crucial for improving quality of life.

What is Celiac Disease?

Unlike SIBO, celiac disease is an autoimmune condition.

It's triggered when the immune system mistakenly attacks the lining of the small intestine after consuming gluten—a protein found in wheat, barley, and rye. This immune response damages the intestinal lining (the villi) in your small intestine, leading to inflammation and impaired nutrient absorption.

Common symptoms of celiac disease include:

Chronic diarrhea or constipation
Abdominal pain and bloating
Fatigue and brain fog
Unexplained weight loss or difficulty maintaining a healthy weight
Signs of malnutrition, such as anemia, brittle nails, or thinning hair

However, not everyone with celiac disease experiences obvious digestive symptoms.

Some people may struggle with "non-classical" symptoms, like joint pain, migraines, depression, or infertility. This wide range of manifestations often makes celiac disease difficult to diagnose, with many individuals going years—if not decades—without answers.

What makes celiac disease particularly challenging is its lifelong nature. Gluten exposure, even in small amounts like just a crumb, can reignite the immune response, which damages the intestinal lining (the villi), impairing the body's ability to absorb nutrients. This requires not just dietary changes but a complete lifestyle shift to avoid cross-contamination in food, cookware, and even cosmetics.

What is gluten?

Gluten is a type of protein found naturally in certain grains, including:

Wheat (found in bread, pasta, baked goods)
Barley (used in malt products, beer, and soups)
Rye (commonly in rye bread and cereals)
Triticale (a hybrid of wheat and rye).

Gluten acts as a "glue" that holds food together, giving dough its elasticity and helping it maintain its shape. This is why gluten is so crucial in baking—it gives bread that soft, chewy texture we all recognize.

Beyond obvious foods like bread and pasta, gluten is found in many unsuspecting products, including:

Sauces and dressings (soy sauce, gravies)
Processed snacks and candy
Soups and broths
Beer and malt beverages
Personal care products (lip balms, shampoos)

Even small amounts of gluten, such as cross-contamination from shared cooking surfaces or utensils, can trigger symptoms in individuals with celiac disease. This is why strict gluten avoidance is necessary for recovery.

For those without celiac disease but with gluten sensitivity (non-celiac gluten sensitivity, NCGS) or other gut issues, gluten can still cause bloating, fatigue, and inflammation. Understanding gluten and its impact is key to managing symptoms and supporting gut health.

Similarities between SIBO and Celiac Disease

It's easy to see why SIBO and celiac disease are often confused.

Both conditions can cause damage to the small intestine or disrupt its functionality. Therefore, both of them share similar symptoms, such as chronic bloating, diarrhea, fatigue, and other discomforts that disrupt daily life.

People with either condition might find themselves misdiagnosed with IBS (irritable bowel syndrome) or dismissed altogether, leaving them frustrated and desperate for answers.

Here's where the overlap happens:

Digestive distress: Both SIBO and celiac disease can lead to bloating, abdominal pain, and irregular bowel movements. These symptoms often worsen after eating, making it difficult to pinpoint specific triggers.
Nutrient deficiencies: Malabsorption is a hallmark of both conditions. In SIBO, bacterial overgrowth can "steal" nutrients from your food before your body has a chance to absorb them. In celiac disease, intestinal damage hinders the absorption of critical nutrients like iron and calcium.
Fatigue and brain fog: Whether caused by nutrient deficiencies or systemic inflammation, both conditions can leave you feeling drained and unfocused, affecting your ability to work, socialize, or even enjoy daily activities.
Emotional impact: Living with unexplained symptoms can feel isolating and stressful. Both conditions are known to take a toll on mental health, with many sufferers experiencing anxiety, depression, or a sense of hopelessness.

However, the similarities end there. While SIBO is fundamentally a bacterial imbalance, celiac disease involves an autoimmune reaction to gluten. This distinction is key to understanding how each condition is diagnosed and treated.

Key differences between SIBO and Celiac Disease

While SIBO and celiac disease share similar symptoms, their underlying causes and diagnostic approaches are entirely different. Here's a breakdown of the key differences:

Mechanisms:

- SIBO: A bacterial imbalance caused by an overgrowth of microbes in the small intestine.
- Celiac disease: An autoimmune condition where the body attacks the small intestine in response to gluten.

Triggers:

- SIBO: This can be caused by poor gut motility, structural abnormalities, reduced protective mechanisms, or the use of medications. It's often exacerbated by carbohydrate-heavy meals – even on a gluten-free diet, which feed the overgrown bacteria.
- Celiac disease: Triggered by consuming gluten, which is found in wheat, barley, rye, and certain processed foods. It's also common to have a negative response to dairy and soy due to cross-reactions.

Markers:

- SIBO: Diagnosed through breath tests or, in rare cases, small intestine aspirates.
- Celiac disease: Identified via blood tests (tTG-IgA, DGP), intestinal biopsy, and genetic testing. In some cases, a comprehensive stool test can also indicate reactions to gluten (but doesn't equal a diagnostic tool).

Understanding these differences is essential for pinpointing the right diagnosis and creating an effective treatment plan.

Diagnostic criteria and tools

Diagnosing SIBO

The gold standard for diagnosing SIBO is the lactulose or glucose breath test, which measures hydrogen and methane gases produced by bacteria and archaea in the small intestine. (If you live in the USA, the TrioSmart test can also measure hydrogen sulfide gas production.) Elevated levels of these gases after consuming a sugar solution indicate bacterial overgrowth or Intestinal Methanogen Overgrowth (IMO).

However, it's important to be aware that breath tests can sometimes produce false positives or negatives. So, it's important to evaluate symptoms and medical history in conjunction with test results to arrive at the right conclusion.

Diagnosing Celiac Disease

Diagnosing celiac disease requires a multi-step approach:

Blood tests: Screening tests, such as tissue transglutaminase (tTG-IgA) or deamidated gliadin peptide (DGP), are the first step.
Intestinal biopsy: If blood tests are positive, a biopsy of the small intestine confirms the diagnosis by identifying villous atrophy (damage to the gut lining). The patient needs to consume gluten before performing this type of test.
Genetic testing: In ambiguous cases, the HLA-DQ2 and HLA-DQ8 genes are often tested to rule out celiac disease. While these genes are not diagnostic, their absence makes celiac disease very unlikely.

The SIBO-Celiac Disease connection

Did you know that celiac disease can predispose you to SIBO?

Here's how the two conditions are linked:

Intestinal damage: In celiac disease, chronic inflammation can damage the small intestine, leading to impaired motility and an environment conducive to bacterial overgrowth.
Nutrient deficiencies: A lack of nutrients like zinc and magnesium, often seen in celiac disease, can hinder gut healing and motility.
Delayed diagnosis: Undiagnosed or untreated celiac disease increases the risk of developing SIBO due to prolonged intestinal damage.

A 2019 study published in Gut found that individuals with celiac disease are significantly more likely to develop SIBO compared to the general population. This highlights the importance of testing for both conditions if symptoms persist after adopting a gluten-free diet.

Treatment for Celiac Disease

The cornerstone of treating celiac disease is a strict lifelong gluten-free diet, which allows the gut lining to heal and inflammation to subside.

Here's a closer look at the process:

Eliminating gluten: Even trace amounts of gluten from cross-contamination can trigger a reaction. This requires diligence when dining out, shopping for groceries, and preparing meals at home.
Healing the gut: Anti-inflammatory foods, bone broth, and supplements like L-glutamine and zinc can support gut repair.
Managing nutrient deficiencies: Many people with celiac disease require supplementation for iron, B12, and fat-soluble vitamins to restore optimal levels.

Holistic approach toward SIBO with Celiac Disease

If you're dealing with SIBO and celiac disease, a one-size-fits-all treatment plan won't work. A functional, holistic approach is key to addressing both conditions simultaneously.

Steps to address SIBO:

Boosting gut motility: Prokinetics, such as ginger or motility agents (natural or pharmaceutical), can prevent bacterial stagnation in the small intestine.
Reducing the overgrowth: Antimicrobial herbs (e.g., berberine, oregano oil) or prescription antibiotics (like rifaximin) may be used to reduce bacterial load.
Supporting the gut microbiome: Managing SIBO doesn't just stop with an elimination protocol. Prebiotics and probiotics tailored to individual needs help restore balance without worsening symptoms.
Dietary adjustments: A low-FODMAP diet is often used temporarily to reduce symptoms while treating the root causes. However, it is also important to incorporate anti-inflammatory nutrients such as omega-3 fatty acids, turmeric, and polyphenol-rich foods, as these can reduce inflammation and support healing.
Lifestyle changes:

- Stress impacts the gut-brain axis, worsening symptoms. Incorporating stress-relief techniques like mindfulness, yoga, or deep breathing can support healing.
- Quality sleep promotes gut motility and overall healing. Aim for 7-9 hours per night.
- Gentle exercise, such as walking, yoga, or Pilates, improves gut motility and reduces stress.
- Slowing down at meals, chewing thoroughly, and creating a calm eating environment can improve digestion and reduce bloating.

Enzymatic support: Digestive enzymes and bitters can aid nutrient absorption.
Detox pathways: Enhancing liver function with cruciferous vegetables, dandelion tea, or milk thistle can support overall healing.

Addressing both conditions in tandem can improve symptoms, restore balance, and reclaim quality of life.

A case study

When one of my clients first came to me, she was struggling with constant bloating, fatigue, and a restricted diet that felt impossible to manage.

After performing a comprehensive stool test (GI MAP), several red flags were showing up:

Inadequate production of digestive enzymes
Impaired detoxification
Possible signs of intestinal bleeding
signs of intestinal inflammation
immune system activation and a potential gluten sensitivity
Increased risk for an increased intestinal permeability ("leaky gut")

Client case Celiac disease

I referred the client to a gastroenterologist for further evaluation, which confirmed a diagnosis of celiac disease. In her case, no SIBO was detected.

From there, we developed a personalized protocol that included:

Transitioning to a strict gluten-free diet to avoid triggering immune responses
Supporting gut motility to prevent bacterial overgrowth
Boosting digestive enzyme production
Incorporating anti-inflammatory nutrients and a fiber-rich diet to support the growth of beneficial bacteria, which were also low on her test
Supporting the detoxification pathways

Within six months, the client reported feeling more energetic, less bloated, and more in control of her life. As she put it, "Working with Alexandra finally gave me answers to why I was feeling so bloated, tired, irritated, and gassy...She helped me get to the root causes of all my symptoms."

Conclusion

SIBO and celiac disease may look similar on the surface, but their causes, diagnostic criteria, and treatments are entirely different. Understanding these differences—and their potential connection—can help you get the right diagnosis and embark on a path to healing.

If you're struggling with persistent gut issues, don't settle for temporary solutions. A holistic approach that addresses the root causes of your symptoms can help you reclaim your life. Remember, with the right tools, support, and mindset, healing is within reach!

References

References:

SIBO-related sources:

Dukowicz, A. C., Lacy, B. E., & Levine, G. M. (2007). Small intestinal bacterial overgrowth: a comprehensive review. Gastroenterology & hepatology, 3(2), 112–122.
Cho, Y. K., Lee, J., & Paik, C. N. (2023). Prevalence, risk factors, and treatment of small intestinal bacterial overgrowth in children. Clinical and experimental pediatrics, 66(9), 377–383. https://doi.org/10.3345/cep.2022.00969
Khoshini, R., Dai, SC., Lezcano, S. et al.A Systematic Review of Diagnostic Tests for Small Intestinal Bacterial Overgrowth. Dig Dis Sci 53, 1443–1454 (2008). https://doi.org/10.1007/s10620-007-0065-1
Sharabi, E., Rezaie, A. Small Intestinal Bacterial Overgrowth. Curr Infect Dis Rep26, 227–233 (2024). https://doi.org/10.1007/s11908-024-00847-7
Ghoshal UC, Shukla R, Ghoshal U. Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome: A Bridge between Functional Organic Dichotomy. Gut and Liver 2017;11:196-208. https://doi.org/10.5009/gnl16126
Lim, J., & Rezaie, A. (2023). Pros and Cons of Breath Testing for Small Intestinal Bacterial Overgrowth and Intestinal Methanogen Overgrowth. Gastroenterology & hepatology, 19(3), 140–146.
Rezaie, Ali MD, MSc, FRCP(C)1; Buresi, Michelle MD2; Lembo, Anthony MD3; Lin, Henry MD4; McCallum, Richard MD5; Rao, Satish MD6; Schmulson, Max MD7; Valdovinos, Miguel MD8; Zakko, Salam MD9; Pimentel, Mark MD, FRCP(C)1 on behalf of The North American Consensus group on hydrogen and methane-based breath testing. Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus. American Journal of Gastroenterology 112(5):p 775-784, May 2017. | DOI: 10.1038/ajg.2017.46

Celiac disease related sources:

Parzanese, I., Qehajaj, D., Patrinicola, F., Aralica, M., Chiriva-Internati, M., Stifter, S., Elli, L., & Grizzi, F. (2017). Celiac disease: From pathophysiology to treatment. World journal of gastrointestinal pathophysiology, 8(2), 27–38. https://doi.org/10.4291/wjgp.v8.i2.27
Caio, G., Volta, U., Sapone, A. et al.Celiac disease: a comprehensive current review. BMC Med 17, 142 (2019). https://doi.org/10.1186/s12916-019-1380-z
Lebwohl, B., Sanders, D. S., & Green, P. H. R. (2018). Coeliac disease. Lancet (London, England), 391(10115), 70–81. https://doi.org/10.1016/S0140-6736(17)31796-8
Parzanese, I., Qehajaj, D., Patrinicola, F., Aralica, M., Chiriva-Internati, M., Stifter, S., Elli, L., & Grizzi, F. (2017). Celiac disease: From pathophysiology to treatment. World journal of gastrointestinal pathophysiology, 8(2), 27–38. https://doi.org/10.4291/wjgp.v8.i2.27
Niland, B., & Cash, B. D. (2018). Health Benefits and Adverse Effects of a Gluten-Free Diet in Non-Celiac Disease Patients. Gastroenterology & hepatology, 14(2), 82–91.
Barbaro, M. R., Cremon, C., Stanghellini, V., & Barbara, G. (2018). Recent advances in understanding non-celiac gluten sensitivity. F1000Research, 7, F1000 Faculty Rev-1631. https://doi.org/10.12688/f1000research.15849.1

SIBO-Celiac disease relationship related sources:

Losurdo, G., Marra, A., Shahini, E., Girardi, B., Giorgio, F., Amoruso, A., Pisani, A., Piscitelli, D., Barone, M., Principi, M., Di Leo, A., & Ierardi, E. (2017). Small intestinal bacterial overgrowth and celiac disease: A systematic review with pooled-data analysis. Neurogastroenterology and motility, 29(6), 10.1111/nmo.13028. https://doi.org/10.1111/nmo.13028
Shah, A., Thite, P., Hansen, T., Kendall, B. J., Sanders, D. S., Morrison, M., Jones, M. P., & Holtmann, G. (2022). Links between celiac disease and small intestinal bacterial overgrowth: A systematic review and meta-analysis. Journal of Gastroenterology and Hepatology, 37(12), 2311–2321. https://doi.org/10.1111/jgh.15920
Evans KE, Higham S, Smythe A, et al Small bowel bacterial overgrowth in coeliac disease: a cause of presenting symptoms?.Gut 2011;60:A83-A84. https://gut.bmj.com/content/60/Suppl_1/A83.2
Sroka, N., Rydzewska-Rosołowska, A., Kakareko, K., Rosołowski, M., Głowińska, I., & Hryszko, T. (2023). Show Me What You Have Inside—The Complex Interplay between SIBO and Multiple Medical Conditions—A Systematic Review. Nutrients, 15(1), 90. https://doi.org/10.3390/nu15010090
Patel, Akash & Vaghani, Utsav & Mehta, Sarang & Sri, Shivaramakrishna. (2023). Celiac Disease and Upper Gastrointestinal Microbiota Disorders: A Meta-Analysis Investigating Small Intestinal Bacterial Overgrowth (SIBO) and H. pylori. 2. 1-11. 10.5281/zenodo.10066586.
Catassi, C., Alaedini, A., Bojarski, C., Bonaz, B., Bouma, G., Carroccio, A., Castillejo, G., De Magistris, L., Dieterich, W., Di Liberto, D., Elli, L., Fasano, A., Hadjivassiliou, M., Kurien, M., Lionetti, E., Mulder, C. J., Rostami, K., Sapone, A., Scherf, K., Schuppan, D., … Sanders, D. S. (2017). The Overlapping Area of Non-Celiac Gluten Sensitivity (NCGS) and Wheat-Sensitive Irritable Bowel Syndrome (IBS): An Update. Nutrients, 9(11), 1268. https://doi.org/10.3390/nu9111268
Charlesworth, R. P. G., & Winter, G. (2020). Small intestinal bacterial overgrowth and Celiac disease – coincidence or causation? Expert Review of Gastroenterology & Hepatology, 14(5), 305–306. https://doi.org/10.1080/17474124.2020.1757428

SIBO vs Celiac Disease: symptoms, diagnosis, and the critical connection you need to know Read More »